Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Humana, Inc. v. Mallinckrodt ARD LLC et al
Case Number:
2:19-cv-06926
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
May 27, 2021
Judge Questions Bid To Move Acthar Cases To Delaware
A member of the Judicial Panel on Multidistrict Litigation on Thursday questioned Mallinckrodt ARD LLC's push to have a battery of antitrust cases over sales of the anti-seizure drug Acthar transferred to federal court in Delaware where the company is currently making its way through bankruptcy proceedings.
-
January 28, 2021
Mallinckrodt Seeks To Move Acthar Cases To Delaware
Mallinckrodt has urged federal courts around the country to transfer cases involving the drugmaker's hormone treatment Acthar that make claims for antitrust, racketeering and other violations to the Delaware court overseeing its bankruptcy.
-
August 14, 2020
Mallinckrodt Must Face Antitrust Claims Over Seizure Drug
Mallinckrodt Ard LLC must face claims by Humana Inc. that it ran a scheme to keep a competitor to its infant spasm drug off the market after a California federal judge on Friday allowed the bulk of the claims in the suit to go forward.
-
May 26, 2020
Mallinckrodt Wants More Cuts To Seizure Drug Price Suit
Mallinckrodt has asked a California federal judge to cut more antitrust claims from Humana's $700 million price-gouging lawsuit over an infant seizure syndrome treatment, claiming the insurer yet again defined the market too narrowly.
-
March 11, 2020
Humana Missed Mark On Market In Seizure Drug Suit
A California federal judge has cut antitrust claims from Humana's suit accusing Mallinckrodt of orchestrating an "outrageous" price-gouging scheme for a hormone gel after finding problems with how the insurer defined the market, but left racketeering and state law claims intact.
-
October 29, 2019
Mallinckrodt Defends Price Hike As Necessary To Save Drug
Mallinckrodt has urged a California federal judge to toss Humana's $700 million price-gouging lawsuit over an infant seizure syndrome treatment, arguing that the insurer cannot rely on settlements with federal antitrust enforcers to get around the fact that massive price increases were required to keep the therapy in production.
-
August 09, 2019
Humana Says Acthar's Meteoric Price Hike Cost It $700M
Mallinckrodt ran "one of the most outrageous price-gouging schemes in the history of American medicine" on its hormone gel used primarily to treat an infant seizure syndrome, according to a new suit filed by Humana, which says the scheme has cost it more than $700 million.